Home › Funds › MPM BioImpact LLC › URGN
MPM BioImpact LLC position in URGN
UROGEN PHARMA LTD · Health Care
MPM BioImpact LLC reported holding 933,415 shares of URGN (UROGEN PHARMA LTD) in its Q2 2026 13F filing — a position valued at US$34.3M, representing 2.09% of its reported portfolio and ranking #18 among its reported holdings. MPM BioImpact LLC has disclosed URGN holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How MPM BioImpact LLC's URGN position evolved
MPM BioImpact LLC first disclosed a stake in URGN in Q3 2025 at 135,000 shares (US$2.7M). The position peaked in Q2 2026 at 933,415 shares, worth US$34.3M. Across 4 filings, MPM BioImpact LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 933,415 shares valued at US$34.3M — a reduction of -10,388 shares quarter over quarter.. Notable position changes include a 597% increase in Q4 2025 (shares fell 23% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 135.00K | $2.69M | New |
| Q4 2025 | 941.38K | $22.05M | Add |
| Q1 2026 | 943.80K | $16.97M | Hold |
| Q2 2026 | 933.41K | $34.35M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About URGN and 13F data
URGN (UROGEN PHARMA LTD) is a Health Care company. 39 other funds we track also report a position in URGN — the largest reported positions include RTW INVESTMENTS, LP (US$167.2M), Kynam Capital Management, LP (US$89.6M), Jefferies Financial Group Inc. (US$80.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding URGN
- RTW INVESTMENTS, LP 4.54M sh · $167.22M · Q2 2026
- Kynam Capital Management, LP 2.43M sh · $89.58M · Q2 2026
- Jefferies Financial Group Inc. 2.20M sh · $80.95M · Q2 2026
- ACORN CAPITAL ADVISORS, LLC 1.67M sh · $61.58M · Q2 2026
- Opaleye Management Inc. 1.44M sh · $52.99M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 1.30M sh · $47.91M · Q2 2026
- Soleus Capital Management, L.P. 829.81K sh · $30.54M · Q2 2026
- Boxer Capital Management, LLC 500.00K sh · $18.40M · Q2 2026
- Privium Fund Management B.V. 210.00K sh · $7.73M · Q2 2026
- SUPERSTRING CAPITAL MANAGEMENT LP 191.31K sh · $7.04M · Q2 2026
More on MPM BioImpact LLC
FAQ
How long has MPM BioImpact LLC held URGN?
MPM BioImpact LLC has disclosed URGN holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is MPM BioImpact LLC's current position in URGN?
As of Q2 2026, MPM BioImpact LLC holds 933.41K shares of URGN (UROGEN PHARMA LTD), valued at $34.35M, representing 2.09% of its reported portfolio and ranking #18.
Has MPM BioImpact LLC been buying or selling URGN?
In the latest 13F filing (Q2 2026), MPM BioImpact LLC reduced its position in URGN. The position peaked in Q2 2026 at 933.41K shares.
Which other funds hold URGN?
Other major institutional holders of URGN include RTW INVESTMENTS, LP, Kynam Capital Management, LP, Jefferies Financial Group Inc., among 39 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.